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(RILD). RILD is typically described as consisting of an early phase of 
transient radiation pneumonitis and a late phase of persistent fibrosis. 
Previous studies have documented a local increase in radiological 
density as a function of the locally delivered dose. However, in these 
investigations only NSCLC patients receiving simple non-IMRT 
techniques were considered and little response has typically been 
observed in the low dose regions (5-10 Gy). The present study 
investigates time-dependent dose-response relationships of healthy 
lung tissue for NSCLC patients treated by IMRT. 
Materials and Methods: The study comprises 132 NSCLC patients 
treated with IMRT delivered as static field step-and-shoot or VMAT 
between October 2007 to August 2012 to a prescribed dose of 60 or 66 
Gy in 2 Gy fractions. Each patient had a series of follow-up CT scans 
which were co-registered (Elastix) to the planning CT scan using 
deformable registration. Follow-up scans were excluded from the 
study after clinical or radiological evidence of local recurrence or 
development of metastases in the thoracic region, leaving 390 
successful registrations eligible for further analysis. 3D maps of lung 
density changes were created by a voxel-by-voxel subtraction of the 
planning CT from the co-registered follow-up CT. The planned dose 
distribution was correlated to the map of density changes within the 
healthy lung tissue. The population average response was investigated 
by binning the individual dose-response curves in time intervals after 
the commencement of radiotherapy. 
Results: The figure shows the population average dose response at 
different time intervals after radiotherapy. Within the first 3 months, 
a significant increase in lung density was observed for all dose 
intervals (P<0.0001). In this time interval the density change from 
baseline increases as function of dose and reaches a plateau around 
45 Gy. At later intervals the response function changed appearance. 
The response in regions receiving 5-45 Gy decreased compared to 3 
months (P=0.014), while the plateau was replaced by a peak at high 
doses. At 6 months, regions receiving 55-60 Gy exhibited an increase 
inresponse compared to 3 months (P=0.013). After 6 months, regions 
receiving 45-60 Gy also displayed a decreased response (P=0.026). 
After 15 months the response stabilized at all dose intervals. 
Conclusions: NSCLC patients treated by modern radiotherapy 
techniques exhibit a significant increase in density of healthy lung 
tissue even at low dose levels (5-10 Gy). The transient nature of the 
response is indicative of radiation pneumonitis, while the eventual 
stabilization of the response likely is associated with fibrosis. The 
temporal evolution of the response differs in the high- and low-dose 
region. This finding suggests distinct dose-dependent time 
characteristics for the development of radiation pneumonitis and 
fibrosis. 
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Purpose/Objective: The use of parotid gland (PG) sparing intensity-
modulated radiotherapy (IMRT) significantly reduces high grade 
xerostomia. Water alone is a poor oral mucosal lubricant; the 
inorganic and organic salivary components are suggested to increase 
moisture retention on the mucosa. PG saliva comprises ~70% and 30% 
of stimulated and unstimulated saliva volume respectively. Despite 
the use of PG sparing IMRT, rates of high grade xerostomia are ~35% at 
1 year. Data on saliva composition analysis post radiotherapy (RT) is 
limited pre-IMRT due to poor residual salivary flow. We present an 
analysis of PG saliva flow rate and composition for patients treated 
with IMRT within four trials at The RMH. 
Materials and Methods: Samples were collected in the PARSPORT trial 
(CRUK/003/005) and 3 single institution, phase 2 studies (Midline (CCR 
2588), Dose Escalation (CCR1978) and Nasopharynx (CCR 2608)). 
Stimulated and unstimulated PG salivas were collected from right and 
left glands using Lashley cups (2% citric acid). Collect was at baseline 
(BL), 3, 6, 12 and 24 months(m) post-IMRT. Samples were suitable for 
analysis if a pre-IMRT and chemotherapy (BL) and ≥1 subsequent 
sample, of adequate volume (>150µl) were collected. Salivas were 
analysed for protein and ionic components using ELISA (IgA, B2M and 
lactoferrin), BCA assay (total protein) and ICP-mass spectrometry 
(Ca2+, Na+). Flow rates were determined gravitometrically (1g=1ml). 
Samples were statistically analysed for early (3-6m post-IMRT) and 
late (12-24m post-IMRT) changes using wilcoxon signed rank or paired 
t-tests and reported as % change from BL. 
Results: Twenty-one patients provided 120 samples for analysis. 
Seventeen patients were male, mean patient age was 58.4 yr and 14 
received chemotherapy. Mean PG RT dose was 27.8Gy. Sequential 
results (table 1) showed significant changes in several parameters a 
persistent (early and late) increase in lactoferrin. An early increase in 
B2M and Na+ concentration and an early decrease in PG saliva flow 
rate. Both resolved to normal after 12m. Stimulated calcium 
concentration (Ca2+) was persistently decreased by ~20%. All other 
parameters were not significantly altered. 
 
 
% of BL (100%), Median 
(IQR) 
Unstimulated PG Saliva 
(*=p<0.05) 
% of BL (100%), Median 
(IQR) 
Stimulated PG saliva 
(*=p<0.05) 
Parameter 3-6m (n=24) 
12-24m 
(n=12) 
3-6m 
(n=17) 
12-24m 
(n=12 
Total Protein 
Concentration n.s. n.s. n.s. n.s.  
Total Protein 
Secretion Rate 
38.0%* 
(10.7-
101.0) 
n.s. n.s. n.s.  
PG Saliva Flow 
Rate 
39.3%* 
(25.0-
120.8) 
n.s. 45.1%* (21.0-99.2) n.s.  
IgA 
Concentration n.s. n.s. n.s. n.s.  
B2M 
Concentration 
130.4%* 
(77.6-
200.9) 
n.s. 
125.2%* 
(98.4-
224.3) 
n.s. 
LF Concentration 
289.5%* 
(119.7-
626.7) 
386.9%* 
(574.4-
641.6) 
279.1%* 
(165.6-
583.5) 
225.5%* 
(89.4-
317.6) 
Ca2+ 
Concentration n.s. n.s. 
77.7%* 
(63.9-
83.7) 
80.5%* 
(73.1-
107.2) 
Na+ 
Concentration n.s. n.s. 
126.2%* 
(114.3-
345.2) 
n.s. 
 
Conclusions: An elevated Na+ concentration suggests transient ductal 
dysfunction. Salivary flow rates returned to baseline after 12 months 
indicating good functional recovery post IMRT. Persistently reduced 
Ca2+ concentration may affect mucin-mucin interactions and mucin 
retention with water on the buccal mucosa. This may also have a 
negative impact on long-term dental remineralisation. 
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Purpose/Objective: Since December 2011, we planned adjuvant 
radiotherapy for breast cancer with fixed angle Intensity Modulated 
Radiation Therapy (IMRT) and Volumetric Modulated Arc Therapy 
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(VMAT). We present our clinical experience in the first patients (> 6 
months follow-up) to emphasize tolerance to low dose exposure. 
Materials and Methods: We reviewed 198 patients (mean age 55 range 
32-75): 121 were treated for left sided, 72 right sided and 5 for 
bilateral disease. Approximately half of the patients had an indication 
for lymph node irradiation. Patients were treated with an integrated 
boost (SIB) of 50.4/64.4Gy (n=89) or 50/#2Gy(n=32) or with 
42.6/#2.66Gy (START) and 10/#2.5Gy sequential boost (n=66). Sixteen 
patients (> 70 yrs) received 5x (+2x boost) 6.5 Gy weekly. Patients 
were seen weekly and at 1, 3 and 6 month after treatment. Potential 
risk factors for toxicity were tested in 2x2 tables (Fisher´s exact). The 
planning target volume dose was prescribed 95% (maximum< 108%), 
with objectives for respectively, ipsilateral lung (V20Gy<20-30%, 
V5Gy<60-65%), other lung (V5Gy<20%), heart (V10Gy<50%, V35Gy<10%) 
with maximum <35Gy, and contralateral breast (V5Gy<0.5-1%)with 
maximum <10Gy. All dose volume comparisons were adjusted to 
abiological equivalent dose of 2Gy/ fraction.  
Results: During planning VMAT plans were often abandoned (85%) 
mainly because of V5, and alternative IMRT was selected for 
treatment. VMAT plans selected for treatment resulted in higher V10 
in heart (19.7 versus 13.7%), V5 of contralateral breast (0.8 versus 
0.4%) and lung V5 (66.8 versus 63.8). For bilateral, however, VMAT 
resulted in better dose distributions. One bilateral treatment 
consistedof SIB, all others of START, being easier to set up and better 
tolerated. Almost no dermatitis (13% grade 2) or cosmetic 
deterioration was observed. Dry cough was observed in 18% of patients 
and 8 patients) needed medication (pneumonitisgrade 2 RTOG). Plans 
were reviewed and those patients with dry cough showed oftenlung V5 
over 70%. Among other risk factors tested (table 1) lung V5 exposure 
over 70% appeared strongly associated with pneumonitis. After the 
first analysis, we decided to not accept any planning with V5 over 70% 
and no new clinical pneumonitis has appeared since.  
  
Conclusions: IMRT results in less V5 exposure than VMAT planning of 
breast patients. High V5 lung values clearly increase pneumonitis risk. 
More research on low dose exposure is needed to create guidelines for 
dose constraints. Systematic comparison of IMRT to VMAT can 
optimize future planning in breast cancer patients. 
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Purpose/Objective: The development of proton and ion acceleration 
by ultra high intensity lasers for cancer therapy promises the 
realization of compact and economic particle accelerators that can be 
integrated in already existing clinics. For translational research 
towards clinical application the radiobiological consequences of laser 
accelerated and therewith ultra-short pulsed particle beams with high 
pulse dose have to be investigated. After extensive in vitro dose 
response studies with laser driven electron and proton beams, in vivo 
experiments have been performed within the joint research project 
'onCOOPtics' as next translational step. 
Materials and Methods: A mouse tumor model suitable for currently 
available low energy laser protons was developed, tested and 
successfully used. The already in vitro established laser based 
irradiation technology was further developed for the animal model in 
terms of beam transport, beam monitoring, dose delivery and 
dosimetry allowing to apply a prescribed dose to each tumor and to 
determine the absolute dose received. For precise and reproducible 
positioning at the irradiation site a system for mouse fixation, tumor 
positioning and position verification was implemented as described in 
[Schürer et al 2012]. Experiments were carried out at the 30 Terawatt 
Jena Titanium:Sapphire (JeTi) laser system. Laser pulses of 28 fs 
duration were focused into a hydrogen gas jet accelerating electrons 
to energies of up to a few 10 MeV. In vivo tumor irradiation was 
realized for murine sarcoma KHT and human squamous cell carcinoma 
FaDu. Dose sup to 14 Gy were applied at mean dose rates of 1-2 
Gy/min and irradiation induced tumor growth delay was investigated. 
Comparison irradiations were performed at a conventional therapy 
LINAC with the same setup for irradiation and absolute dose 
determination.  
Results: The reliability and stability of all implemented setup 
components and methods were proven by numerous irradiations over a 
period of several months. Dose response curves of tumor growth delay 
were generated for direct comparison of ultra short pulsed laser 
accelerated and conventional continuous electron beam. The ongoing 
data evaluation by now shows no significant difference in RBE for laser 
driven electrons. 
Conclusions: The successful establishment of all technical 
requirements for and the world wide first performance of systematic 
animal studies with laser accelerated electrons mark an important 
step towards the clinical application of laser accelerated particle 
beams. The realization of in vivo studies with laser driven proton 
beams is now feasible.  
The authors thank for the contribution of the Jeti accelerator crew at 
Friedrich-Schiller-University Jena, Ralf Bergmann (HZDR) and for the 
support by the German Ministry of Education and Research (BMBF) 
grant no. 03Z1N511. 
Reference: Schürer et al; Irradiation system for pre-clinical studies 
with laser accelerated electrons; Biomed Tech 2012; 57(Suppl. 1) 
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Purpose/Objective: For treatment planning with carbon ions, the 
local effect model (LEM) is used to predict the relative biological 
effectiveness (RBE) in normal and tumor tissue. Uncertainties in the 
predicted RBEs translate into uncertainty of the prescribed dose, 
which can lead to severe side effects. Therefore, the RBE-models have 
to be validated using experimental data. In a previous study in rat [1], 
the RBE for late reactions of the cervical spinal cord after irradiation 
with carbon ions was measured in the entrance region and at the 
center of a 10 mm spread-out-Bragg-peak (SOBP). A significant 
dependence of the RBE and the fractionation parameter α/β on LET 
was found. Based on this study, we systematically extend this 
database to several intermediate LET-values. 
Materials and Methods: Experiments were performed at the 
experimental beam line at the Heidelberg Heavy Ion Beam Therapy 
Center (HIT). The cervical spinal cord of female Sprague-Dawley rats 
